1. Home
  2. ARL vs TRDA Comparison

ARL vs TRDA Comparison

Compare ARL & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Realty Investors Inc.

ARL

American Realty Investors Inc.

HOLD

Current Price

$21.12

Market Cap

261.7M

Sector

Real Estate

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$7.69

Market Cap

274.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARL
TRDA
Founded
1999
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Building operators
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
261.7M
274.5M
IPO Year
1999
2021

Fundamental Metrics

Financial Performance
Metric
ARL
TRDA
Price
$21.12
$7.69
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$21.00
AVG Volume (30 Days)
11.6K
287.3K
Earning Date
05-08-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
206.59
N/A
EPS
N/A
N/A
Revenue
$50,014,000.00
$25,421,000.00
Revenue This Year
N/A
$39.97
Revenue Next Year
N/A
$50.80
P/E Ratio
N/A
N/A
Revenue Growth
5.70
N/A
52 Week Low
$12.42
$4.93
52 Week High
$24.44
$16.45

Technical Indicators

Market Signals
Indicator
ARL
TRDA
Relative Strength Index (RSI) 69.62 53.92
Support Level $14.97 $5.75
Resistance Level N/A $10.82
Average True Range (ATR) 1.10 0.50
MACD 0.68 0.23
Stochastic Oscillator 67.14 80.10

Price Performance

Historical Comparison
ARL
TRDA

About ARL American Realty Investors Inc.

American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments: the acquisition, development, ownership and management of multifamily properties (Residential Segment) and the acquisition, ownership and management of commercial real estate properties (Commercial Segment). Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: